Provider Briefing: Clomiphene Citrate Availability in 2026

Clomiphene Citrate has been a cornerstone of ovulation induction therapy since its FDA approval in the 1960s. For reproductive endocrinologists, OB/GYNs, and primary care providers who prescribe it, understanding the current supply landscape is essential to maintaining continuity of care for patients undergoing time-sensitive fertility treatment.

This briefing covers the supply chain status, prescribing considerations, cost and access factors, and tools available to help your patients find Clomiphene in stock.

Supply Chain Timeline

The Clomiphene supply chain has undergone significant disruption over the past several years:

• 2022: Endo Pharmaceuticals declared bankruptcy amid opioid litigation. The Clomid brand was divested to Cosette Pharmaceuticals, a subsidiary of Avista Capital Partners.
• October 2022: Cosette began distributing Clomid 50 mg tablets, restoring brand-name supply.
• 2022-2023: Par Pharmaceuticals discontinued its generic clomiphene citrate tablets (50 mg, unit-dose blister packs in 10-count and 30-count configurations — NDC 49884-0701-54 and NDC 49884-0701-55). This reduced the number of generic manufacturers in the market.
• 2024-2025: Supply stabilized but remained inconsistent at the retail pharmacy level, with some regions experiencing intermittent stock-outs.
• 2026: Clomiphene is not listed on the FDA drug shortage database. Availability is generally adequate but can be pharmacy-dependent.

Prescribing Implications

The supply situation has several practical implications for prescribers:

Treatment Timing Sensitivity

Clomiphene therapy is cycle-dependent, typically initiated on day 3 or day 5 of the menstrual cycle. A delay of even 2-3 days in filling a prescription can result in a lost treatment cycle for the patient. Prescribers should consider:

• Sending prescriptions to the pharmacy as early as possible in the cycle — ideally before day 1
• Verifying pharmacy stock before prescribing, or directing patients to pharmacies known to carry fertility medications
• Providing patients with tools to check availability, such as Medfinder for Providers

Alternative Considerations

Given the supply variability, having a documented plan for alternative therapy is advisable:

• Letrozole (Femara) 2.5-7.5 mg daily x 5 days: Increasingly favored as first-line for PCOS-related anovulation per ASRM guidelines. Letrozole has demonstrated comparable or superior live birth rates in PCOS patients and is widely available as a generic.
• Gonadotropins (Follistim, Gonal-F, Menopur): Appropriate for patients who have failed oral ovulation induction agents. Higher cost and monitoring requirements limit broad applicability.
• Compounded Clomiphene Citrate: Some compounding pharmacies can prepare clomiphene citrate capsules when commercial tablets are unavailable. Verify state regulations and ensure quality standards are met.

For more on alternatives, see our patient-facing article on alternatives to Clomiphene.

Current Availability Picture

While Clomiphene is not formally in shortage, retail availability varies significantly:

• Large chain pharmacies (CVS, Walgreens, Rite Aid) may not consistently stock Clomiphene due to lower dispensing volumes compared to chronic disease medications
• Independent pharmacies often have more flexibility to order from multiple wholesalers and may maintain more reliable stock
• Specialty fertility pharmacies are the most reliable source, as they specifically cater to reproductive medicine prescriptions
• Mail-order and telehealth-affiliated pharmacies can bypass local stock issues entirely

Cost and Access Considerations

Cost remains a significant barrier for many fertility patients, as insurance coverage for fertility medications is inconsistent:

Pricing Overview

• Generic clomiphene citrate 50 mg (5 tablets / 1 cycle): $85-$100 cash price
• Generic clomiphene with discount coupon (30 tablets): approximately $100-$115
• Brand Clomid (30 tablets) retail: $363-$415
• Brand Clomid with manufacturer savings card (Cosette): $70 (insured) to $135 (cash-pay)

Insurance Landscape

• Many commercial plans cover Clomiphene but may require prior authorization and documented infertility diagnosis
• Some plans categorically exclude fertility medications
• Medicare Part D generally does not cover fertility medications
• States with fertility insurance mandates (currently 21 states) may require coverage of ovulation induction medications

Patient Assistance

• Cosette Pharmaceuticals offers a Clomid Pharmacy Savings Card at myclomid.com/savings
• GoodRx, SingleCare, and RxSaver coupons can reduce generic clomiphene costs by 40-60%
• NeedyMeds.org and RxAssist.org list generic medication assistance programs

For a comprehensive patient guide on cost savings, see how to save money on Clomiphene.

Tools and Resources for Your Practice

Medfinder for Providers is a free tool that helps you and your staff direct patients to pharmacies with Clomiphene in stock. Key features:

• Real-time pharmacy availability search by medication and location
• Covers chain, independent, and specialty pharmacies
• Can be shared directly with patients as a self-service resource

Additionally, consider:

• Establishing a relationship with a preferred specialty fertility pharmacy for your practice
• Building Clomiphene availability into your patient counseling workflow — inform patients at the time of prescribing that they may need to check multiple pharmacies
• Keeping Letrozole as a documented backup in your treatment protocols

Looking Ahead

The Clomiphene market remains concentrated among a small number of manufacturers, which means the supply chain is vulnerable to disruption. Providers should:

• Monitor ASHP and FDA shortage databases periodically
• Maintain current alternative treatment protocols
• Educate patients proactively about potential pharmacy stock variability
• Consider Letrozole as a first-line or co-first-line agent where clinically appropriate

Final Thoughts

Clomiphene Citrate remains an effective and affordable fertility medication, but the supply landscape in 2026 requires providers to be proactive about access. By leveraging tools like Medfinder for Providers, establishing preferred pharmacy relationships, and maintaining documented alternative treatment plans, you can help ensure your patients don't lose valuable treatment cycles to pharmacy stock-outs.

For patient-facing information you can share with your patients, see our 2026 Clomiphene shortage update for patients and how to find Clomiphene in stock.